ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosis
Published 2 years ago • 604 plays • Length 3:05Download video MP4
Download video MP3
Similar videos
-
1:42
momelotinib vs. ruxolitinib in myelofibrosis patients with thrombocytopenia
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:59
pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
13:56
myelofibrosis treatment options
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
2:23
future therapies for mf: pacritinib, momelotinib, fedratinib & other pathways
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:27
real-world use of fedratinib in patients with mf who have failed on ruxolitinib
-
1:58
current research into jak inhibitors - specifially ruxolitinib, pacritinib, and momelotinib
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
1:06
fedratinib: mpn-associated myelofibrosis
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
2:55
novel combinations with ruxolitinib being investigated for myelofibrosis
-
1:22
real-world outcomes of patients with mf treated with fedratinib post-ruxolitinib discontinuation
-
0:46
xport-mf-034: selinexor plus ruxolitinib in jak-inhibitor naïve myelofibrosis